The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease, Alzheimers Dement. J. Alzheimers Assoc, vol.7, pp.263-269, 2011. ,
The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease, Alzheimers Dement. J. Alzheimers Assoc, vol.7, pp.270-279, 2011. ,
Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease, Alzheimers Dement. J. Alzheimers Assoc, vol.7, pp.280-292, 2011. ,
Introduction to Revised Criteria for the Diagnosis of Alzheimer's Disease: National Institute on Aging and the Alzheimer Association Workgroups, Alzheimers Dement. J. Alzheimers Assoc, vol.7, pp.257-262, 2011. ,
Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria, Lancet Neurol, vol.13, pp.614-629, 2014. ,
A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers, Neurology, vol.87, pp.539-547, 2016. ,
Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF, Neurology, vol.52, pp.1555-1562, 1999. ,
CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis, Lancet Neurol, vol.15, pp.673-684, 2016. ,
, CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease, vol.129, pp.3035-3041, 2006.
CSF biomarkers for Alzheimer disease correlate with cortical brain biopsy findings, Neurology, vol.78, pp.1568-1575, 2012. ,
CSF Abeta 42 levels correlate with amyloidneuropathology in a population-based autopsy study, Neurology, vol.60, pp.652-656, 2003. ,
Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia, Neurobiol. Aging, vol.29, pp.1143-1159, 2008. ,
Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study, Lancet Neurol, vol.5, pp.228-234, 2006. ,
CSF phosphorylated tau in the diagnosis and prognosis of mild cognitive impairment and Alzheimer's disease: a meta-analysis of 51 studies, J. Neurol. Neurosurg. Psychiatry, vol.80, pp.966-975, 2009. ,
Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke, Neurosci. Lett, vol.297, pp.187-190, 2001. ,
Alzheimer's biomarkers, 2017. ,
, Alzheimers Dement. Diagn. Assess. Dis. Monit, vol.6, pp.143-151
The clinical use of structural MRI in Alzheimer disease, Nat. Rev. Neurol, vol.6, pp.67-77, 2010. ,
Magnetic resonance imaging and positron emission tomography in the diagnosis of neurodegenerative dementias, Funct. Neurol, vol.31, pp.205-215, 2017. ,
Positron Emission Tomography in Evaluation of Dementia: Regional Brain Metabolism and Long-term Outcome, JAMA, vol.286, pp.2120-2127, 2001. ,
Alzheimer disease: operating characteristics of PET-a meta-analysis, Radiology, vol.231, pp.73-80, 2004. ,
Neuroimaging and Other Biomarkers for Alzheimer's Disease: The Changing Landscape of Early Detection, Annu. Rev. Clin. Psychol, vol.9, pp.621-648, 2013. ,
Update on hypothetical model of Alzheimer's disease biomarkers, Lancet Neurol, vol.12, pp.207-216, 2013. ,
The dynamics of Alzheimer's disease biomarkers in the Alzheimer's Disease Neuroimaging Initiative cohort, Neurobiol. Aging, vol.31, pp.1263-1274, 2010. ,
Relations between hypometabolism in the posterior association neocortex and hippocampal atrophy in Alzheimer's disease: a PET/MRI correlative study, J. Neurol. Neurosurg. Psychiatry, vol.71, pp.315-321, 2001. ,
Hippocampal formation glucose metabolism and volume losses in MCI and AD, Neurobiol. Aging, vol.22, pp.529-539, 2001. ,
Relative Capability of MR Imaging and FDG PET to Depict Changes Associated with Prodromal and Early Alzheimer Disease, Radiology, vol.256, pp.932-942, 2010. ,
Mini-mental state": A practical method for grading the cognitive state of patients for the clinician, J. Psychiatr. Res, vol.12, pp.189-198, 1975. ,
Cerebrospinal Fluid Amyloid ?42/Phosphorylated Tau Ratio Discriminates Between Alzheimer's Disease and Vascular Dementia, J. Gerontol. Ser. A, vol.61, pp.755-758, 2006. ,
Alzheimer CSF biomarkers in routine clinical setting, Acta Neurol. Scand, vol.125, pp.416-423, 2012. ,
Difference in imaging biomarkers of neurodegeneration between early and late-onset amnestic Alzheimer's disease, Neurobiol. Aging, vol.54, pp.22-30, 2017. ,
, R: A language and environment for statistical computing. R Foundation for Statistical Computing, 2017.
Association of elevated phospho-tau levels with Alzheimer-typical 18F-fluoro-2-deoxyD-glucose positron emission tomography findings in patients with mild cognitive impairment, Biol. Psychiatry, vol.56, pp.279-283, 2004. ,
CSF phosporylated TAU protein levels correlate with cerebral glucose metabolism assessed with PET in Alzheimer's disease, Brain Res. Bull, vol.76, pp.80-84, 2008. ,
Hypometabolism and Altered Cerebrospinal Fluid Markers in Normal Apolipoprotein E E4 Carriers with Subjective Memory Complaints, Biol. Psychiatry, vol.63, pp.609-618, 2008. ,
, Relationships between biomarkers in aging and dementia, vol.73, pp.1193-1199, 2009.
Basal Cerebral Metabolism May Modulate the Cognitive Effects of A? in Mild Cognitive Impairment: An Example of Brain Reserve, J. Neurosci. Off. J. Soc. Neurosci, vol.29, p.14770, 2009. ,
PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease, Brain, vol.139, pp.1551-1567, 2016. ,
Impact of tau and amyloid burden on glucose metabolism in Alzheimer's disease, Ann. Clin. Transl. Neurol, vol.3, pp.934-939, 2016. ,
Imaging in-vivo tau pathology in Alzheimer's disease with THK5317 PET in a multimodal paradigm, Eur. J. Nucl. Med. Mol. Imaging, vol.43, pp.1686-1699, 2016. ,
CSF total and phosphorylated tau protein, regional glucose metabolism and dementia severity in Alzheimer's disease, Eur. J. Neurol, vol.15, pp.1155-1162, 2008. ,
Neuropathological stageing of Alzheimer-related changes, Acta Neuropathol. (Berl.), vol.82, pp.239-259, 1991. ,
The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer's disease, Neurology, vol.52, pp.1158-1165, 1999. ,
Decreased CSF A?42 correlates with brain atrophy in cognitively normal elderly, Ann. Neurol, vol.65, pp.176-183, 2009. ,
The association between biomarkers in cerebrospinal fluid and structural changes in the brain in patients with Alzheimer's disease, J. Intern. Med, vol.275, pp.418-427, 2014. ,
Cerebrospinal fluid biomarkers for disease stage and intensity in cognitively impaired patients, Neurosci. Lett, vol.339, pp.99-102, 2003. ,
Larger temporal volume in elderly with high versus low beta-amyloid deposition, Brain, vol.133, pp.3349-3358, 2010. ,
Education, occupation, leisure activities, and brain reserve: a population-based study, Neurobiol. Aging, vol.33, pp.15-423, 2012. ,
Education increases reserve against Alzheimer's disease-evidence from structural MRI analysis, Neuroradiology, vol.54, pp.929-938, 2012. ,
Effects of demographic factors on cortical thickness in Alzheimer's disease, Neurobiol. Aging, vol.32, pp.200-209, 2011. ,
MRI-assessed atrophy subtypes in Alzheimer's disease and the cognitive reserve hypothesis, PLOS ONE, vol.12, 2017. ,
A neuroimaging approach to capture cognitive reserve: Application to Alzheimer's disease. Hum, Brain Mapp, vol.38, pp.4703-4715, 2017. ,
Compensatory mechanisms in higher-educated subjects with Alzheimer's disease: a study of 20 years of cognitive decline, Brain, vol.137, pp.1167-1175, 2014. ,
Cognitive reserve in ageing and Alzheimer's disease, Lancet Neurol, vol.11, pp.1006-1012, 2012. ,
Education and rates of cognitive decline in incident Alzheimer's disease, J. Neurol. Neurosurg. Psychiatry, vol.77, pp.308-316, 2006. ,
Multimodal Neuroimaging in Alzheimer's Disease: Early Diagnosis, Physiopathological Mechanisms, and Impact of Lifestyle, J. Alzheimers Dis. JAD, 2018. ,
Direct voxel-based comparison between grey matter hypometabolism and atrophy in Alzheimer's disease, Brain, vol.131, pp.60-71, 2008. ,
Comparison of the diagnostic performance of FDG-PET and VBM-MRI in very mild Alzheimer's disease, Eur. J. Nucl. Med. Mol. Imaging, vol.33, pp.801-809, 2006. ,
Correlations between FDG PET glucose uptake-MRI gray matter volume scores and apolipoprotein E ?4 gene dose in cognitively normal adults: a cross-validation study using voxel-based multi-modal partial least squares, Neuroimage, vol.60, pp.2316-2322, 2012. ,
, A signed Wilcoxon ranks test adjusted with the Bonferroni method was used in case of significance in the Kruskal Wallis test: For atrophy extent: between G3-G1
G4-G2 (not significant); between G4-G3 (p=0.042) ¤¤: Fisher's exact test ,
, Alzheimer's Disease and Dementia | Alzheimer's Association
Alzheimer's disease and vascular dementia in developing countries: prevalence, management, and risk factors, Lancet Neurol, vol.7, pp.812-826, 2008. ,
Neuropathological stageing of Alzheimer-related changes, Acta Neuropathol. (Berl.), vol.82, pp.239-259, 1991. ,
Phases of A beta-deposition in the human brain and its relevance for the development of AD, Neurology, vol.58, pp.1791-1800, 2002. ,
The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer's disease, Neurology, vol.52, pp.1158-1165, 1999. ,
Introduction to Revised Criteria for the Diagnosis of Alzheimer's Disease: National Institute on Aging and the Alzheimer Association Workgroups, Alzheimers Dement. J. Alzheimers Assoc, vol.7, pp.257-262, 2011. ,
Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease, Alzheimers Dement. J. Alzheimers Assoc, vol.7, pp.280-292, 2011. ,
The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease, Alzheimers Dement. J, 2011. ,
, Alzheimers Assoc, vol.7, pp.263-269
The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on AgingAlzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease, Alzheimers Dement. J. Alzheimers Assoc, vol.7, pp.270-279, 2011. ,
Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria, Lancet Neurol, vol.13, pp.614-629, 2014. ,
, Biomarkers and surrogate endpoints: preferred definitions and conceptual framework, Biomarkers Definitions Working Group, vol.69, pp.89-95, 2001.
, Molecular and Biochemical Markers of Alzheimer's Disease". The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group, Neurobiol. Aging, vol.19, pp.109-116
Use of CSF biomarkers in the diagnosis of Alzheimer's disease in clinical practice, Rev. Neurol, vol.167, pp.474-484, 2011. ,
Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF, Neurology, vol.52, pp.1555-1562, 1999. ,
CSF markers for incipient Alzheimer's disease, Lancet Neurol, vol.2, pp.605-613, 2003. ,
Biomarkers of Alzheimer's Disease, Neurobiol. Dis, vol.35, pp.128-140, 2009. ,
Decreased beta-amyloid1-42 in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease, Neurology, vol.54, pp.1099-1102, 2000. ,
Prediction of Alzheimer's disease using the CSF, 2007. ,
, Abeta42/Abeta40 ratio in patients with mild cognitive impairment, Dement. Geriatr. Cogn. Disord, vol.23, pp.316-320
Fluid and imaging biomarkers for Alzheimer's disease: Where we stand and where to head to, Exp. Gerontol, 2018. ,
CSF phosphorylated tau in the diagnosis and prognosis of mild cognitive impairment and Alzheimer's disease: a meta-analysis of 51 studies, J. Neurol. Neurosurg. Psychiatry, vol.80, pp.966-975, 2009. ,
Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke, Neurosci. Lett, vol.297, pp.187-190, 2001. ,
Association of total tau and phosphorylated tau 181 protein levels in cerebrospinal fluid with cerebral atrophy in mild cognitive impairment and Alzheimer disease, J. Psychiatry Neurosci. JPN, vol.34, pp.136-142, 2009. ,
Alzheimer CSF biomarkers in routine clinical setting, Acta Neurol. Scand, vol.125, pp.416-423, 2012. ,
Analysis of combined CSF biomarkers in AD diagnosis, Clin. Lab, vol.60, pp.629-634, 2014. ,
Cerebrospinal Fluid Amyloid ?42/Phosphorylated Tau Ratio Discriminates Between Alzheimer's Disease and Vascular Dementia, J. Gerontol. Ser. A, vol.61, pp.755-758, 2006. ,
, CSF Biomarkers and Incipient Alzheimer Disease in Patients With Mild Cognitive Impairment, vol.302, pp.385-393, 2009.
Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics, Nat. Rev. Drug Discov, vol.6, pp.295-303, 2007. ,
Cerebrospinal Fluid tau/?-Amyloid42 Ratio as a Prediction of Cognitive Decline in Nondemented Older Adults, Arch. Neurol, vol.64, pp.343-349, 2007. ,
Biomarkers for the Early Detection and Progression of Alzheimer's Disease, Neurotherapeutics, vol.14, pp.35-53, 2017. ,
CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: a follow-up study, Neurology, vol.69, pp.631-639, 2007. ,
Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain, Arch. Neurol, vol.66, pp.382-389, 2009. ,
CSF biomarkers predict a more malignant outcome in Alzheimer disease, Neurology, vol.74, pp.1531-1537, 2010. ,
Diagnosis of Alzheimer’s Disease with [18F]PET in Mild and Asymptomatic Stages, Behav. Neurol, vol.21, pp.101-115, 2009. ,
Core candidate neurochemical and imaging biomarkers of Alzheimer's disease?, Alzheimers Dement, vol.4, pp.38-48, 2008. ,
PreClinical Detection of Alzheimer's Disease Using FDG-PET, with or without Amyloid Imaging, J. Alzheimers Dis. JAD, vol.20, pp.843-854, 2010. ,
Magnetic resonance imaging and positron emission tomography in the diagnosis of neurodegenerative dementias, Funct. Neurol, vol.31, pp.205-215, 2017. ,
FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer's disease, Eur. J. Nucl. Med. Mol. Imaging, vol.36, pp.811-822, 2009. ,
, Brain Imaging in Alzheimer Disease. Cold Spring Harb. Perspect. Med, vol.2, 2012.
What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia, Neurology, vol.69, pp.871-877, 2007. ,
Positron Emission Tomography in Evaluation of Dementia: Regional Brain Metabolism and Long-term Outcome, JAMA, vol.286, pp.2120-2127, 2001. ,
Multicenter Standardized 18F-FDG PET Diagnosis of Mild Cognitive Impairment, Alzheimer's Disease, and Other Dementias, J. Nucl. Med. Off, 2008. ,
, Publ. Soc. Nucl. Med, vol.49, pp.390-398
Performance of FDG PET for detection of Alzheimer's disease in two independent multicentre samples (NEST-DD and ADNI), Dement. Geriatr. Cogn. Disord, vol.28, pp.259-266, 2009. ,
Imaging markers for Alzheimer disease, Neurology, vol.81, pp.487-500, 2013. ,
Combined Evaluation of FDG-PET and MRI Improves Detection and Differentiation of Dementia, PLoS ONE, vol.6, 2011. ,
, , pp.14-25, 2005.
MCI conversion to dementia and the APOE genotype: a prediction study with FDG-PET, Neurology, vol.63, pp.2332-2340, 2004. ,
Positron Emission Tomography in Evaluation of Dementia: Regional Brain Metabolism and Long-term Outcome, JAMA, vol.286, p.2120, 2001. ,
Fluorodeoxyglucose-Positron-Emission Tomography, Single-Photon Emission Tomography, and Structural MR Imaging for Prediction of Rapid Conversion to Alzheimer Disease in Patients with Mild Cognitive Impairment: A Meta-Analysis, Am. J. Neuroradiol, vol.30, pp.404-410, 2009. ,
Prediction of cognitive decline in normal elderly subjects with 2-[18F]fluoro-2-deoxy-dglucose/positron-emission tomography (FDG/PET), Proc. Natl. Acad. Sci. U. S. A, vol.98, pp.10966-10971, 2001. ,
18 F-FDG PET for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI), 2015. ,
, Cochrane Database Syst. Rev, vol.1, p.10632
Medicine O behalf of the EA of N (2015) A Cochrane review on brain [<Superscript>18</Superscript>F]FDG PET in dementia: limitations and future perspectives, Eur. J. Nucl. Med. Mol. Imaging, vol.42, pp.1487-1491 ,
Clinical validity of brain fluorodeoxyglucose positron emission tomography as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework, Neurobiol. Aging, vol.52, pp.183-195, 2017. ,
Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates, J. Neurol. Neurosurg. Psychiatry, vol.55, pp.967-972, 1992. ,
Voxel-Based Morphometry-The Methods, NeuroImage, vol.11, pp.805-821, 2000. ,
DOI : 10.1006/nimg.2000.0582
URL : http://www.stat.wisc.edu/~mchung/teaching/MIA/reading/VBM.ashburner.2000.pdf
The clinical use of structural MRI in Alzheimer disease, Nat. Rev. Neurol, vol.6, pp.67-77, 2010. ,
Neuroimaging and Other Biomarkers for Alzheimer's Disease: The Changing Landscape of Early Detection, Annu. Rev. Clin. Psychol, vol.9, pp.621-648, 2013. ,
Medial temporal lobe atrophy on MRI differentiates Alzheimer's disease from dementia with Lewy bodies and vascular cognitive impairment: a prospective study with pathological verification of diagnosis, Brain, vol.132, pp.195-203, 2009. ,
Amnestic Mild Cognitive Impairment: Structural MR Imaging Findings Predictive of Conversion to Alzheimer Disease, Am. J. Neuroradiol, vol.29, pp.944-949, 2008. ,
Direct voxel-based comparison between grey matter hypometabolism and atrophy in Alzheimer's disease, Brain, vol.131, pp.60-71, 2008. ,
Comparison of 18F-FDG PET and Optimized Voxel-Based Morphometry for Detection of Alzheimer's Disease: Aging Effect on Diagnostic Performance, J. Nucl. Med, vol.48, pp.1961-1970, 2007. ,
Comparison of the diagnostic performance of FDG-PET and VBM-MRI in very mild Alzheimer's disease, Eur. J. Nucl. Med. Mol. Imaging, vol.33, pp.801-809, 2006. ,
Hippocampal formation glucose metabolism and volume losses in MCI and AD, Neurobiol. Aging, vol.22, pp.529-539, 2001. ,
Distinct pattern of hypometabolism and atrophy in preclinical and predementia Alzheimer's disease, Neurobiol. Aging, vol.35, pp.1973-1981, 2014. ,
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B, Ann. Neurol, vol.55, pp.306-319, 2004. ,
Post-mortem correlates of in vivo PiBPET amyloid imaging in a typical case of Alzheimer's disease, Brain, vol.131, pp.1630-1645, 2008. ,
A review of neuroimaging biomarkers of Alzheimer's disease. Neurol, Asia, vol.18, pp.239-248, 2013. ,
, Vivo Imaging of Amyloid Deposition in Alzheimer's Disease using the Novel Radioligand, vol.51, pp.913-920, 2010.
Imaging characteristic of dual-phase (18)F-florbetapir (AV45/Amyvid) PET for the concomitant detection of perfusion deficits and betaamyloid deposition in Alzheimer's disease and mild cognitive impairment, 2016. ,
, J. Nucl. Med. Mol. Imaging, vol.43, pp.1304-1314
Lexical factors and cerebral regions influencing verbal fluency performance in MCI, Neuropsychologia, vol.54, pp.98-111, 2014. ,
Amyloid Imaging with 18FFlorbetaben in Alzheimer Disease and Other Dementias, J. Nucl. Med, vol.52, pp.1210-1217, 2011. ,
Cerebral amyloid-? PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study, Florbetaben Study Group, vol.10, pp.424-435, 2011. ,
18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: A phase 2 trial, Ann. Neurol, vol.68, pp.319-329, 2010. ,
Clinical Validation of 18F-AZD4694, an Amyloid-?-Specific PET Radioligand, J. Nucl. Med, vol.53, pp.415-424, 2012. ,
Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans, Ann. Neurol, vol.59, pp.512-519, 2006. ,
Amyloid PET imaging in Alzheimer's disease: A comparison of three radiotracers, Eur. J. Nucl. Med. Mol. Imaging, vol.41, pp.1398-1407, 2014. ,
Diagnostic accuracy of 18F amyloid PET tracers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis, Eur. J. Nucl, 2016. ,
, Mol. Imaging, vol.43, pp.374-385
PET imaging of amyloid deposition in patients with mild cognitive impairment, Neurobiol. Aging, vol.29, pp.1456-1465, 2008. ,
Biomarkers of Alzheimer's disease and mild cognitive impairment: A current perspective, 2015. ,
, Adv. Med. Sci, vol.60, pp.76-82
, Alzheimers Dement. J. Alzheimers Assoc, vol.14, pp.293-305, 2018.
11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease, Neurology, vol.67, pp.446-452, 2006. ,
Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia, JAMA, vol.313, pp.1924-1938, 2015. ,
Tau imaging: early progress and future directions, Lancet Neurol, vol.14, pp.114-124, 2015. ,
Alzheimer's disease, and other neurodegenerative conditions, Curr. Opin, 2016. ,
, , vol.36, pp.43-51
In vivo tau PET imaging in dementia: Pathophysiology, radiotracer quantification, and a systematic review of clinical findings, Ageing Res. Rev, vol.36, pp.50-63, 2017. ,
Tau PET imaging: present and future directions, Mol. Neurodegener, vol.12, 2017. ,
Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer's disease, NeuroImage, vol.157, pp.448-463, 2017. ,
Non-invasive assessment of Alzheimer's disease neurofibrillary pathology using 18F-THK5105 PET, Brain, vol.137, pp.1762-1771, 2014. ,
A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers, Neurology, vol.87, pp.539-547, 2016. ,
Update on hypothetical model of Alzheimer's disease biomarkers, Lancet Neurol, vol.12, pp.207-216, 2013. ,
Alzheimer's disease: the amyloid cascade hypothesis, Science, vol.256, pp.184-185, 1992. ,
Brain Injury Biomarkers Are Not Dependent on ?-amyloid in Normal Elderly, Ann. Neurol, vol.73, pp.472-480, 2013. ,
Amyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivity, Neurology, vol.81, pp.1732-1740, 2013. ,
DOI : 10.1212/01.wnl.0000435556.21319.e4
URL : http://n.neurology.org/content/81/20/1732.full.pdf
Biomarker Modeling of Alzheimer's Disease, Neuron, vol.80, pp.1347-1358, 2013. ,
Rates of transition between amyloid and neurodegeneration biomarker states and to dementia among non-demented individuals: a population-based cohort study, Lancet Neurol, vol.15, pp.56-64, 2016. ,
Vulnerable Neural Systems and the Borderland of Brain Aging and Neurodegeneration, Neuron, vol.77, pp.219-234, 2013. ,
Limited agreement between biomarkers of neuronal injury at different stages of Alzheimer's disease, Alzheimers Dement, vol.10, pp.684-689, 2014. ,
Cognitive and Brain Profiles Associated with Current Neuroimaging Biomarkers of Preclinical Alzheimer's Disease, J. Neurosci, vol.35, pp.10402-10411, 2015. ,
The dynamics of Alzheimer's disease biomarkers in the Alzheimer's Disease Neuroimaging Initiative cohort, Neurobiol. Aging, vol.31, pp.1263-1274, 2010. ,
Relations between hypometabolism in the posterior association neocortex and hippocampal atrophy in Alzheimer's disease: a PET/MRI correlative study, J. Neurol. Neurosurg. Psychiatry, vol.71, pp.315-321, 2001. ,
Relative Capability of MR Imaging and FDG PET to Depict Changes Associated with Prodromal and Early Alzheimer Disease, Radiology, vol.256, pp.932-942, 2010. ,
Difference in imaging biomarkers of neurodegeneration between early and late-onset amnestic Alzheimer's disease, Neurobiol. Aging, vol.54, pp.22-30, 2017. ,
Mini-mental state": A practical method for grading the cognitive state of patients for the clinician, J. Psychiatr. Res, vol.12, pp.189-198, 1975. ,
The FAB: a Frontal Assessment Battery at bedside, Neurology, vol.55, pp.1621-1626, 2000. ,
The relation of the trail making test to organic brain damage, J. Consult. Psychol, vol.19, pp.393-394, 1955. ,
Evaluation of visual recognition memory in MCI patients, Neurology, vol.62, pp.1317-1322, 2004. ,
La mémoire collective, mémoire des événements publics et des célébrités : les batteries EVE30 et TOP30, 2006. ,
, , vol.80, 1997.
Visuospatial Judgment: A Clinical Test, Arch. Neurol, vol.35, pp.364-367, 1978. ,
DOI : 10.1001/archneur.1978.00500300038006
Test for the examination of constructional apraxia, Rev. Neurol, vol.102, pp.653-656, 1960. ,
Validation d'une batterie brève d'évaluation des praxies gestuelles pour consultation Mémoire. Évaluation chez 419 témoins, 127 patients atteints de troubles cognitifs légers et 320 patients atteints d'une démence, 2009. ,
DOI : 10.1016/j.neurol.2008.11.016
Multimodal Neuroimaging in Alzheimer's Disease: Early Diagnosis, Physiopathological Mechanisms, and Impact of Lifestyle, J. Alzheimers Dis. JAD, 2018. ,
Correlations between FDG PET glucose uptake-MRI gray matter volume scores and apolipoprotein E ?4 gene dose in cognitively normal adults: a cross-validation study using voxel-based multi-modal partial least squares, Neuroimage, vol.60, pp.2316-2322, 2012. ,
CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis, Lancet Neurol, vol.15, pp.673-684, 2016. ,
Correlation of florbetaben PET imaging and the amyloid peptide Aß42 in cerebrospinal fluid, Psychiatry Res, vol.265, pp.98-101, 2017. ,
Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study, Neurology, vol.68, pp.501-508, 2007. ,
Association of hypometabolism and amyloid levels in aging, normal subjects, Neurology, vol.82, pp.1959-1967, 2014. ,
Impact of tau and amyloid burden on glucose metabolism in Alzheimer's disease, 2016. ,
, 1 : atrophie limitée-hypométabolisme limité ; 2 : atrophie limitée-hypométabolisme étendu 3 : atrophie étendue-hypométabolisme limité, Transl. Neurol, vol.3, pp.934-939